AstraZeneca’s Tagrisso gains new European approval

AstraZeneca (LSE: AZN) has secured European Commission approval for Tagrisso (osimertinib) to treat certain people with locally advanced, unresectable non-small cell lung cancer (NSCLC).

The decision, based on the Phase III LAURA study, positions Tagrisso as the first targeted EGFR inhibitor authorized in the EU for this indication.

Data show the therapy reduced the risk of disease progression or death by 84% compared to placebo, with patients treated with Tagrisso achieving a median progression-free survival of 39.1 months, significantly surpassing the 5.6 months observed with placebo..